Nifty ends lower as crude stays high and global cues weaken
Nifty closed lower as Brent and WTI stayed elevated, overseas markets fell, and options positioning stayed centered near 22,900. Hindustan Zinc posted strong Q2 numbers.
Why the tape looks like this
FII cash +₹1,166 cr vs DII −₹3,661 cr
Foreign buying met by domestic selling — net −₹2,495 cr on the session.
Options pin the tape at 22,900
PCR 0.81 (call-writer edge), spot 22,888.95. Writers own 22,850–22,900. PCR has moved 1.21 → 0.81 since the open.
Electronic Media leads (+3.10%), Leisure Products lags
14 of 14 sector groups are positive — breadth backs the move.
Global Cues
Overnight contextIndia VIX 14.77
Options Board
EOD wrapPCR
1.21 → 0.81
call-writer edge
Max Pain
22,900
Spot
22,888.95
Put Wall
22,850
support
Call Wall
22,900
resistance
Open interest by strike
as of 15:44 ISTInstitutional Flows
Provisional · cash marketFII CASH
+₹1,166 cr
DII CASH
−₹3,661 cr
NET
−₹2,495 cr
net outflow
Key Developments
Since the openSensex, Nifty Tank As Crude Prices Surge And Corporate Earnings Disappoint
Sensex sinks 876 points, Nifty falls 1.11% as Crude oil nears USD 109
Sensex today | Stock Market Highlights: Sensex, Nifty close over 1% lower; private bank, IT stocks push markets lower
Why it matters — Sensex, Nifty, Share Prices : Markets closed over 1 per cent lower on Monday as losses in private banks and IT stocks ov
Sensex, Nifty end lower amid volatile trade and profit booking
Why it matters — Private banks drag benchmarks as crude prices and weak global cues weigh on sentiment, while PSU banks buck the trend
Rupee ends flat as stock slump, importer hedging erodes bounce
Why it matters — The Indian rupee held steady even as it initially surged, influenced by rising dollar demand from importers. However, th
Hindustan Zinc Q2 Results: Net profit skyrockets 142% YoY to Rs 6,412 crore, revenue soars 77%
Why it matters — Hindustan Zinc reported a 142% year-on-year rise in Q2 FY27 net profit to Rs 6,412 crore, while revenue surged 76.5% to
Disc Medicine reports positive phase 3 trial results for EPP drug
Tomorrow
Results · macro · corporate actionsEducational market commentary only. Not SEBI-registered investment advice.










